These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 32000630)

  • 61. Vorapaxar expands antiplatelet options. Which patients may benefit from thrombin receptor antagonism?
    Duerschmied D; Bode C
    Hamostaseologie; 2012; 32(3):221-7. PubMed ID: 22777302
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Acute Limb Ischemia in Peripheral Artery Disease.
    Hess CN; Huang Z; Patel MR; Baumgartner I; Berger JS; Blomster JI; Fowkes FGR; Held P; Jones WS; Katona B; Mahaffey KW; Norgren L; Rockhold FW; Hiatt WR
    Circulation; 2019 Aug; 140(7):556-565. PubMed ID: 31238713
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease.
    Liang Y; Zhu J; Liu L; Anand SS; Connolly SJ; Bosch J; Guzik TJ; O'Donnell M; Dagenais GR; Fox KA; Shestakovska O; Berkowitz SD; Muehlhofer E; Keller L; Yusuf S; Eikelboom JW;
    Cardiovasc Res; 2021 Feb; 117(3):942-949. PubMed ID: 32289159
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial.
    Low Wang CC; Blomster JI; Heizer G; Berger JS; Baumgartner I; Fowkes FGR; Held P; Katona BG; Norgren L; Jones WS; Lopes RD; Olin JW; Rockhold FW; Mahaffey KW; Patel MR; Hiatt WR;
    J Am Coll Cardiol; 2018 Dec; 72(25):3274-3284. PubMed ID: 30573030
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Long-Term Comparative Outcomes of Patients With Peripheral Artery Disease With and Without Concomitant Coronary Artery Disease.
    Chen DC; Singh GD; Armstrong EJ; Waldo SW; Laird JR; Amsterdam EA
    Am J Cardiol; 2017 Apr; 119(8):1146-1152. PubMed ID: 28259239
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial.
    Debus ES; Nehler MR; Govsyeyev N; Bauersachs RM; Anand SS; Patel MR; Fanelli F; Capell WH; Brackin T; Hinterreiter F; Krievins D; Nault P; Piffaretti G; Svetlikov A; Jaeger N; Hess CN; Sillesen HH; Conte M; Mills J; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR; Bonaca MP
    Circulation; 2021 Oct; 144(14):1104-1116. PubMed ID: 34380322
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Dietary intake and cardiovascular outcomes in patients with chronic vascular disease: insights from the COMPASS trial cohort.
    Wan D; Dehghan M; de Souza RJ; Ramasundarahettige C; Eikelboom JW; Bosch J; Maggioni AP; Bhatt DL; Yusuf S; Anand SS
    Eur J Prev Cardiol; 2023 Jun; 30(8):709-718. PubMed ID: 37080912
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial.
    Harskamp RE; Clare RM; Ambrosio G; Held C; Lokhnygina Y; Moliterno DJ; White HD; Aylward PE; Armstrong PW; Mahaffey KW; Harrington RA; Van de Werf F; Wallentin L; Strony J; Tricoci P
    Eur Heart J Acute Cardiovasc Care; 2017 Mar; 6(2):155-163. PubMed ID: 26895973
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar.
    Cheng JW
    Vasc Health Risk Manag; 2016; 12():263-8. PubMed ID: 27366081
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Quantifying the benefit-risk trade-off for individual patients in a clinical trial: principles and antithrombotic case study.
    Pocock SJ; Owen R; Gregson J; Mt-Isa S; Baumgartner R; Ashby D; Stone GW
    J Thromb Haemost; 2024 May; 22(5):1399-1409. PubMed ID: 38280725
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy.
    Weissler EH; Jones WS; Desormais I; Debus S; Mazzolai L; Espinola-Klein C; Nikol S; Nehler M; Sillesen H; Aboyans V; Patel MR
    Atherosclerosis; 2020 Dec; 315():10-17. PubMed ID: 33190107
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial.
    Anand SS; Caron F; Eikelboom JW; Bosch J; Dyal L; Aboyans V; Abola MT; Branch KRH; Keltai K; Bhatt DL; Verhamme P; Fox KAA; Cook-Bruns N; Lanius V; Connolly SJ; Yusuf S
    J Am Coll Cardiol; 2018 May; 71(20):2306-2315. PubMed ID: 29540326
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Incidence and Cost of Major Adverse Cardiovascular Events and Major Adverse Limb Events in Patients With Chronic Coronary Artery Disease or Peripheral Artery Disease.
    Berger A; Simpson A; Bhagnani T; Leeper NJ; Murphy B; Nordstrom B; Ting W; Zhao Q; Berger JS
    Am J Cardiol; 2019 Jun; 123(12):1893-1899. PubMed ID: 31014542
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Review of vorapaxar for the prevention of atherothrombotic events.
    Wang A
    Expert Opin Pharmacother; 2015; 16(16):2509-22. PubMed ID: 26480240
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Role of Vorapaxar After Coronary Revascularization.
    Sharma A; Lavie CJ; Helft G; Chatterjee S; Goel S; Garg A; Mukherjee D; Marmur JD
    Am J Cardiol; 2016 Apr; 117(7):1059-64. PubMed ID: 26851961
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
    Patel MR; Becker RC; Wojdyla DM; Emanuelsson H; Hiatt WR; Horrow J; Husted S; Mahaffey KW; Steg PG; Storey RF; Wallentin L; James SK
    Eur J Prev Cardiol; 2015 Jun; 22(6):734-42. PubMed ID: 24830710
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease.
    Gryka RJ; Buckley LF; Anderson SM
    Drugs R D; 2017 Mar; 17(1):65-72. PubMed ID: 28063023
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a "CASPAR like" outcome from VOYAGER PAD.
    Bonaca MP; Szarek M; Debus ES; Nehler MR; Patel MR; Anand SS; Muehlhofer E; Berkowitz SD; Haskell LP; Bauersachs RM
    Clin Cardiol; 2022 Dec; 45(12):1143-1146. PubMed ID: 36251249
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Antithrombotic therapy in peripheral artery disease.
    Foley TR; Waldo SW; Armstrong EJ
    Vasc Med; 2016 Apr; 21(2):156-69. PubMed ID: 26823456
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50.
    Bohula EA; Aylward PE; Bonaca MP; Corbalan RL; Kiss RG; Murphy SA; Scirica BM; White H; Braunwald E; Morrow DA
    Circulation; 2015 Nov; 132(20):1871-9. PubMed ID: 26338971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.